To the Editor The study by Rubin et al1 aimed to develop a prognostic score to assess which patients are likely to experience chimeric antigen receptor (CAR) T-cell–associated neurotoxicity. We commend the authors for performing this interesting study, because these helpful results would be useful to guide clinical practice. However, after careful analysis, we would like to point out some important issues raised by the article.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Liu F, Tang X, Zhou L. Risk Factors With Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. JAMA Neurol. 2021;78(6):763–764. doi:10.1001/jamaneurol.2021.0890
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.